Comments on: Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®

Comments on: Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA® https://www.novumpr.nl/2017/06/14/boehringer-ingelheim-presents-phase-iii-results-demonstrating-clinical-equivalence-of-adalimumab-biosimilar-candidate-to-humira/?utm_source=rss&utm_medium=rss&utm_campaign=boehringer-ingelheim-presents-phase-iii-results-demonstrating-clinical-equivalence-of-adalimumab-biosimilar-candidate-to-humira NovumPR press releases Wed, 14 Jun 2017 13:21:45 +0000 hourly 1 https://wordpress.org/?v=6.8.2